Market
Impact on McKinsey's revenue from opioid settlement by end of 2025?
3
Resolution / Starting Odds
Increase • 25%
Decrease • 25%
No significant change • 25%
Uncertain/Other • 25%
McKinsey's financial statements or reports from financial analysts
Story
McKinsey to Pay $650 Million to Settle U.S. Opioid Investigation Linked to Purdue Pharma, Enters Deferred Prosecution Agreement
Dec 13, 2024, 02:58 PM
McKinsey & Company has agreed to pay $650 million to settle a U.S. Department of Justice investigation into its consulting work with Purdue Pharma, the maker of OxyContin. The settlement addresses allegations that McKinsey aided Purdue in boosting sales of opioid painkillers, contributing to the ongoing opioid crisis in the United States. As part of the resolution, McKinsey will enter into a five-year deferred prosecution agreement, which allows the firm to avoid criminal charges while acknowledging its role in the opioid epidemic. The settlement was announced during a news conference held at the Moakley Federal Courthouse in Boston, where federal prosecutors outlined the terms of the agreement. This resolution marks a significant moment in the broader legal scrutiny of consulting firms' involvement in the opioid crisis.
View original story
Similar markets
Significant decline in business operations • 25%
No impact on business operations • 25%
Improvement in business operations • 25%
Minor impact on business operations • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Less than $1 billion • 25%
More than $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Significant Increase • 25%
Moderate Increase • 25%
No Change • 25%
Decrease • 25%
Other • 25%
U.S. Department of Justice • 25%
Federal Trade Commission • 25%
Securities and Exchange Commission • 25%
Teva Pharmaceuticals • 25%
Other • 25%
Endo International • 25%
Johnson & Johnson • 25%